Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098228 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 686
- Enrollment target
NCT00098228: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT00098228 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 686 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (416% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00098228, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 686 participants
- Enrollment target
Study Summary
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Interventions
- DRUG QAB149
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2004-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00098228 record still lists
NCT00098228 is an interventional study that assigns participants to a tested intervention. The registered 686 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (416% higher).
The record links to 0 conditions, and to 1 intervention - of which QAB149 is the first listed.
NCT00098228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00098228 about?
NCT00098228 is a clinical study titled "Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
What is the current status of trial NCT00098228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 686 participants. The study started on 2004-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00098228?
The interventions under investigation include: QAB149 (DRUG).
Who is sponsoring clinical trial NCT00098228?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00098228's enrollment target sits among peer trials
686 47th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- NCT06618274 · 686 participants · NA
Effectiveness of Central Oncology Navigation and the Use of an ORN
- NCT06899126 · 686 participants · Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia